Maternal and Neonatal Efficacy and Safety Outcomes of Myo-inositol in Women With or at High Risk of Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis

To guarantee the healthy development of a fetus, a woman’s metabolism and hormones undergo essential changes throughout pregnancy (1). Insulin production increases with gestational age to better feed the growing fetus with glucose. However, this state can increase the chance of the woman developing gestational diabetes mellitus (GDM) if the increased insulin production is not well regulated by insulin secretion from increased β-cell mass and responsiveness (2). Pregnancy-onset glucose intolerance of any severity that does not meet the criteria for full-blown diabetes is considered to be GDM (3). A growing number of pregnant women are experiencing difficulties such as preeclampsia and are having babies with complications such as macrosomia, hyperbilirubinemia, newborn hypoglycemia, and the need for admission to the neonatal intensive care unit (NICU) because of this condition (4,5).